Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

Michael A. Pfaller; D. J. Diekema; L. Steele-Moore; G. Denys; C. Staley; J. R. Dipersio; M. Saubolle; M. L. Wilson; G. D. Overturf; L. R. Peterson; P. C. Schreckenberger; G. V. Doern; S. Cavalieri; S. Kehl; S. Brecher; L. Lee; H. Isenberg; D. Hardy; D. S. Koga; J. Fusco; M. Hoffmann; S. Swanzy; P. R. Murray; P. Southern; A. Wanger; B. Reisner; J. Snyder; S. Jenkin; K. Hazen; R. Rennie; D. Hoban; R. Davidson; B. Toye; A. Simor; S. Richardson; H. Robson; J. Smayvsky; J. M. Casellas; J. L.M. Sampaio; V. Prado; P. Garcia; J. A. Robledo; J. S. Osornio; C. Zoccoli; A. Reis; M. Guzman; D. A. Schwab; K. Carroll; K. Chapin-Robertson; P. Bourbeau; S. E. Sharp; A. L. Barth; M. J. Struelens; V. Jarlier; J. Nguyen; M. Roussel-Delvallez; N. Legakis; N. Keller; A. Pascual; J. Linares; R. Canton; F. Prapian; J. Bille; D. Gur; V. Korten; L. Mulazimoglu; S. Unal; S. Kocagoz; E. Debbia; G. French; J. Etienne; G. Raponi; I. Rankin; G. Nicoletti; G. Fadda; H. Hanberger; S. Rangel-Fausto; A. C. Rodloff; E. Smyth; K. Christiansen; G. Coombs; S. Kohno; Y. Miyazaki; F. J. Schmitz; A. C. Fluit; D. Costa; P. Appelbaum; D. Bruckner; V. Chaturvedi; G. Hall; C. Kauffman; I. Sobel; B. Suh; K. Van Horn; J. Finquelievich; I. N. Tiraboschi; A. L. Colombo; H. H. Crewe-Brown; D. Roditi

doi:10.1111/j.1470-9465.2004.t01-1-00844.x

Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

Michael A. Pfaller, D. J. Diekema, L. Steele-Moore, G. Denys, C. Staley, J. R. Dipersio, M. Saubolle, M. L. Wilson, G. D. Overturf, L. R. Peterson, P. C. Schreckenberger, G. V. Doern, S. Cavalieri, S. Kehl, S. Brecher, L. Lee, H. Isenberg, D. Hardy, D. S. Koga, J. FuscoM. Hoffmann, S. Swanzy, P. R. Murray, P. Southern, A. Wanger, B. Reisner, J. Snyder, S. Jenkin, K. Hazen, R. Rennie, D. Hoban, R. Davidson, B. Toye, A. Simor, S. Richardson, H. Robson, J. Smayvsky, J. M. Casellas, J. L.M. Sampaio, V. Prado, P. Garcia, J. A. Robledo, J. S. Osornio, C. Zoccoli, A. Reis, M. Guzman, D. A. Schwab, K. Carroll, K. Chapin-Robertson, P. Bourbeau, S. E. Sharp, A. L. Barth, M. J. Struelens, V. Jarlier, J. Nguyen, M. Roussel-Delvallez, N. Legakis, N. Keller, A. Pascual, J. Linares, R. Canton, F. Prapian, J. Bille, D. Gur, V. Korten, L. Mulazimoglu, S. Unal, S. Kocagoz, E. Debbia, G. French, J. Etienne, G. Raponi, I. Rankin, G. Nicoletti, G. Fadda, H. Hanberger, S. Rangel-Fausto, A. C. Rodloff, E. Smyth, K. Christiansen, G. Coombs, S. Kohno, Y. Miyazaki, F. J. Schmitz, A. C. Fluit, D. Costa, P. Appelbaum, D. Bruckner, V. Chaturvedi, G. Hall, C. Kauffman, I. Sobel, B. Suh, K. Van Horn, J. Finquelievich, I. N. Tiraboschi, A. L. Colombo, H. H. Crewe-Brown, D. Roditi

Résultat de recherche: Article › examen par les pairs

353 Citations (Scopus)

Résumé

We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for Clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI.

Langue d'origine	English
Pages (de-à)	11-23
Nombre de pages	13
Journal	Clinical Microbiology and Infection
Volume	10
Numéro de publication	SUPPL. 1
DOI	https://doi.org/10.1111/j.1470-9465.2004.t01-1-00844.x
Statut de publication	Published - mars 2004
Publié à l'externe	Oui

Note bibliographique

Funding Information:
The International Fungal Surveillance Program was supported in part by research grants from Bristol-Myers Squibb (SENTRY Program), Pfizer (ARTEMIS Program) and Schering Plough (Global Surveillance Program).

ASJC Scopus Subject Areas

Microbiology (medical)
Infectious Diseases

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1111/j.1470-9465.2004.t01-1-00844.x

Autres fichiers et liens

Citer

Pfaller, M. A., Diekema, D. J., Steele-Moore, L., Denys, G., Staley, C., Dipersio, J. R., Saubolle, M., Wilson, M. L., Overturf, G. D., Peterson, L. R., Schreckenberger, P. C., Doern, G. V., Cavalieri, S., Kehl, S., Brecher, S., Lee, L., Isenberg, H., Hardy, D., Koga, D. S., ... Roditi, D. (2004). Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clinical Microbiology and Infection, 10(SUPPL. 1), 11-23. https://doi.org/10.1111/j.1470-9465.2004.t01-1-00844.x

Pfaller, MA, Diekema, DJ, Steele-Moore, L, Denys, G, Staley, C, Dipersio, JR, Saubolle, M, Wilson, ML, Overturf, GD, Peterson, LR, Schreckenberger, PC, Doern, GV, Cavalieri, S, Kehl, S, Brecher, S, Lee, L, Isenberg, H, Hardy, D, Koga, DS, Fusco, J, Hoffmann, M, Swanzy, S, Murray, PR, Southern, P, Wanger, A, Reisner, B, Snyder, J, Jenkin, S, Hazen, K, Rennie, R, Hoban, D, Davidson, R, Toye, B, Simor, A, Richardson, S, Robson, H, Smayvsky, J, Casellas, JM, Sampaio, JLM, Prado, V, Garcia, P, Robledo, JA, Osornio, JS, Zoccoli, C, Reis, A, Guzman, M, Schwab, DA, Carroll, K, Chapin-Robertson, K, Bourbeau, P, Sharp, SE, Barth, AL, Struelens, MJ, Jarlier, V, Nguyen, J, Roussel-Delvallez, M, Legakis, N, Keller, N, Pascual, A, Linares, J, Canton, R, Prapian, F, Bille, J, Gur, D, Korten, V, Mulazimoglu, L, Unal, S, Kocagoz, S, Debbia, E, French, G, Etienne, J, Raponi, G, Rankin, I, Nicoletti, G, Fadda, G, Hanberger, H, Rangel-Fausto, S, Rodloff, AC, Smyth, E, Christiansen, K, Coombs, G, Kohno, S, Miyazaki, Y, Schmitz, FJ, Fluit, AC, Costa, D, Appelbaum, P, Bruckner, D, Chaturvedi, V, Hall, G, Kauffman, C, Sobel, I, Suh, B, Van Horn, K, Finquelievich, J, Tiraboschi, IN, Colombo, AL, Crewe-Brown, HH & Roditi, D 2004, 'Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida', Clinical Microbiology and Infection, vol. 10, n° SUPPL. 1, pp. 11-23. https://doi.org/10.1111/j.1470-9465.2004.t01-1-00844.x

@article{4848dc91dc2c4d5c89149d2b77642c3e,

title = "Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida",

abstract = "We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for Clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI.",

author = "Pfaller, {Michael A.} and Diekema, {D. J.} and L. Steele-Moore and G. Denys and C. Staley and Dipersio, {J. R.} and M. Saubolle and Wilson, {M. L.} and Overturf, {G. D.} and Peterson, {L. R.} and Schreckenberger, {P. C.} and Doern, {G. V.} and S. Cavalieri and S. Kehl and S. Brecher and L. Lee and H. Isenberg and D. Hardy and Koga, {D. S.} and J. Fusco and M. Hoffmann and S. Swanzy and Murray, {P. R.} and P. Southern and A. Wanger and B. Reisner and J. Snyder and S. Jenkin and K. Hazen and R. Rennie and D. Hoban and R. Davidson and B. Toye and A. Simor and S. Richardson and H. Robson and J. Smayvsky and Casellas, {J. M.} and Sampaio, {J. L.M.} and V. Prado and P. Garcia and Robledo, {J. A.} and Osornio, {J. S.} and C. Zoccoli and A. Reis and M. Guzman and Schwab, {D. A.} and K. Carroll and K. Chapin-Robertson and P. Bourbeau and Sharp, {S. E.} and Barth, {A. L.} and Struelens, {M. J.} and V. Jarlier and J. Nguyen and M. Roussel-Delvallez and N. Legakis and N. Keller and A. Pascual and J. Linares and R. Canton and F. Prapian and J. Bille and D. Gur and V. Korten and L. Mulazimoglu and S. Unal and S. Kocagoz and E. Debbia and G. French and J. Etienne and G. Raponi and I. Rankin and G. Nicoletti and G. Fadda and H. Hanberger and S. Rangel-Fausto and Rodloff, {A. C.} and E. Smyth and K. Christiansen and G. Coombs and S. Kohno and Y. Miyazaki and Schmitz, {F. J.} and Fluit, {A. C.} and D. Costa and P. Appelbaum and D. Bruckner and V. Chaturvedi and G. Hall and C. Kauffman and I. Sobel and B. Suh and {Van Horn}, K. and J. Finquelievich and Tiraboschi, {I. N.} and Colombo, {A. L.} and Crewe-Brown, {H. H.} and D. Roditi",

note = "Funding Information: The International Fungal Surveillance Program was supported in part by research grants from Bristol-Myers Squibb (SENTRY Program), Pfizer (ARTEMIS Program) and Schering Plough (Global Surveillance Program). ",

year = "2004",

month = mar,

doi = "10.1111/j.1470-9465.2004.t01-1-00844.x",

language = "English",

volume = "10",

pages = "11--23",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier Limited",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Twelve years of fluconazole in clinical practice

T2 - Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

AU - Pfaller, Michael A.

AU - Diekema, D. J.

AU - Steele-Moore, L.

AU - Denys, G.

AU - Staley, C.

AU - Dipersio, J. R.

AU - Saubolle, M.

AU - Wilson, M. L.

AU - Overturf, G. D.

AU - Peterson, L. R.

AU - Schreckenberger, P. C.

AU - Doern, G. V.

AU - Cavalieri, S.

AU - Kehl, S.

AU - Brecher, S.

AU - Lee, L.

AU - Isenberg, H.

AU - Hardy, D.

AU - Koga, D. S.

AU - Fusco, J.

AU - Hoffmann, M.

AU - Swanzy, S.

AU - Murray, P. R.

AU - Southern, P.

AU - Wanger, A.

AU - Reisner, B.

AU - Snyder, J.

AU - Jenkin, S.

AU - Hazen, K.

AU - Rennie, R.

AU - Hoban, D.

AU - Davidson, R.

AU - Toye, B.

AU - Simor, A.

AU - Richardson, S.

AU - Robson, H.

AU - Smayvsky, J.

AU - Casellas, J. M.

AU - Sampaio, J. L.M.

AU - Prado, V.

AU - Garcia, P.

AU - Robledo, J. A.

AU - Osornio, J. S.

AU - Zoccoli, C.

AU - Reis, A.

AU - Guzman, M.

AU - Schwab, D. A.

AU - Carroll, K.

AU - Chapin-Robertson, K.

AU - Bourbeau, P.

AU - Sharp, S. E.

AU - Barth, A. L.

AU - Struelens, M. J.

AU - Jarlier, V.

AU - Nguyen, J.

AU - Roussel-Delvallez, M.

AU - Legakis, N.

AU - Keller, N.

AU - Pascual, A.

AU - Linares, J.

AU - Canton, R.

AU - Prapian, F.

AU - Bille, J.

AU - Gur, D.

AU - Korten, V.

AU - Mulazimoglu, L.

AU - Unal, S.

AU - Kocagoz, S.

AU - Debbia, E.

AU - French, G.

AU - Etienne, J.

AU - Raponi, G.

AU - Rankin, I.

AU - Nicoletti, G.

AU - Fadda, G.

AU - Hanberger, H.

AU - Rangel-Fausto, S.

AU - Rodloff, A. C.

AU - Smyth, E.

AU - Christiansen, K.

AU - Coombs, G.

AU - Kohno, S.

AU - Miyazaki, Y.

AU - Schmitz, F. J.

AU - Fluit, A. C.

AU - Costa, D.

AU - Appelbaum, P.

AU - Bruckner, D.

AU - Chaturvedi, V.

AU - Hall, G.

AU - Kauffman, C.

AU - Sobel, I.

AU - Suh, B.

AU - Van Horn, K.

AU - Finquelievich, J.

AU - Tiraboschi, I. N.

AU - Colombo, A. L.

AU - Crewe-Brown, H. H.

AU - Roditi, D.

N1 - Funding Information: The International Fungal Surveillance Program was supported in part by research grants from Bristol-Myers Squibb (SENTRY Program), Pfizer (ARTEMIS Program) and Schering Plough (Global Surveillance Program).

PY - 2004/3

Y1 - 2004/3

N2 - We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for Clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI.

AB - We determined the species distribution and in-vitro susceptibility of 6082 bloodstream infection (BSI) isolates of Candida spp. collected from 250 medical centres in 32 nations over a 10-year period from 1992 through 2001. The species included 3401 C. albicans, 984 C. glabrata, 796 C. parapsilosis, 585 C. tropicalis, 153 C. krusei, 67 C. lusitaniae, 48 C. guilliermondii, 10 C. famata, 10 C. kefyr, six C. pelliculosa, five C. rugosa, four C. lipolytica, three C. dubliniensis, three C. inconspicua, two C. sake and one isolate each of C. lambica, C. norvegensis and C. zeylanoides. Minimum inhibitory concentration determinations were made using the National Committee for Clinical Laboratory Standards reference broth microdilution method. Variation in the rank order and frequency of the different species of Candida was observed over time and by geographic area. The proportion of BSI due to C. albicans and C. glabrata increased and C. parapsilosis decreased over time in Canada, the USA and Europe. C. glabrata was an infrequent cause of BSI in Latin America and the Asia-Pacific region. Very little variation in fluconazole susceptibility was observed among isolates of C. albicans, C. tropicalis and C. parapsilosis. These species accounted for 78% of all BSI and remained highly susceptible (91-100% susceptible) to fluconazole from 1992 to 2001 irrespective of geographic origin. The prevalence of fluconazole resistance among C. glabrata isolates was variable both over time and among the various countries and regions. Resistance to fluconazole among C. glabrata isolates was greatest in the USA and varied by US census region (range 0-23%). These observations are generally encouraging relative to the sustained usefulness of fluconazole as a systemically active antifungal agent for the treatment of candida BSI.

UR - http://www.scopus.com/inward/record.url?scp=12144286534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144286534&partnerID=8YFLogxK

U2 - 10.1111/j.1470-9465.2004.t01-1-00844.x

DO - 10.1111/j.1470-9465.2004.t01-1-00844.x

M3 - Article

C2 - 14748799

AN - SCOPUS:12144286534

SN - 1198-743X

VL - 10

SP - 11

EP - 23

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - SUPPL. 1

ER -

Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer